Form 4: Sonnet BioTherapeutics Director Albert Dyrness Granted 4,000 Restricted Stock Units

Sonnet BioTherapeutics Holdings, Inc. Director Albert D. Dyrness was granted 4,000 restricted stock units, which will vest by January 8, 2026, and now beneficially owns 4,537 shares of common stock.

Summary

• Director Albert D. Dyrness of Sonnet BioTherapeutics Holdings, Inc. was granted 4,000 restricted stock units (RSUs) on July 11, 2025.
• These RSUs will be settled in shares of common stock, par value $0.0001.
• The RSUs are set to vest 100% on the earlier of January 8, 2026, or upon a 'Change in Control' as defined under the Issuer's 2020 Omnibus Equity Incentive Plan.
• Following this transaction, Mr. Dyrness beneficially owns a total of 4,537 shares of common stock, which includes these unvested RSUs.
• All reported share amounts reflect the company's 1:22 reverse stock split effective August 31, 2023, and a subsequent 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 5

Explanation: The filing is a standard disclosure of an insider equity grant, which is a neutral event. While the mention of past reverse stock splits is a negative historical indicator for the company, the grant itself is a common practice to align director interests with shareholders.

Positives

• The grant of restricted stock units to Director Albert D. Dyrness aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• The clear vesting schedule provides transparency regarding the director's equity compensation.

Negatives

• The document notes two significant reverse stock splits (1:22 on August 31, 2023, and 1:8 on September 30, 2024), which often indicate a company's struggle to maintain a minimum share price or meet exchange listing requirements, potentially signaling underlying financial challenges.

Future Outlook

The 4,000 restricted stock units granted to Director Albert D. Dyrness are scheduled to vest 100% on the earlier of January 8, 2026, or a Change in Control event, aligning his future compensation with company performance.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction and does not contain information directly related to broader industry trends or competitive dynamics within the biotechnology sector.

Related Party Transactions

• Director Albert D. Dyrness, a related party, was granted 4,000 restricted stock units as part of his compensation under the Issuer's 2020 Omnibus Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a director can be viewed as a positive for shareholders as it aligns the director's financial interests with the company's long-term performance and share value. However, the historical reverse stock splits may raise concerns about past share value erosion and the company's financial stability.

Next Steps

• Vesting of 4,000 restricted stock units granted to Director Albert D. Dyrness on or before January 8, 2026.

Key Dates

Keywords

Sonnet BioTherapeutics, SONN, Albert D. Dyrness, Director, Form 4, SEC filing, Restricted Stock Units, RSU, Equity Grant, Beneficial Ownership, Reverse Stock Split, Insider Transaction